Loading…
Protecting America from Seasonal and Pandemic Influenza Act of 2022
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Protecting America from Seasonal and Pandemic Influenza Act of 2022 This bill establishes new, and expands existing, programs and activities to prevent and respond to seasonal and pandemic influenza (flu). In particular, the bill addresses flu vaccine development, manufacturing, and supply chains; genomic sequencing, diagnostic tools, and other technologies to detect, prevent, and respond to flu; and public health communications and related efforts to increase flu vaccination rates and access to antiviral medications. The bill also sets out a process through which Congress may adjust discretionary spending limits to accommodate additional funding for health defense operations (e.g., flu-related activities).
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Budget, and Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
FY2024 Appropriations and supplemental appropriations; H.R. 9476 Protecting America from Seasonal and Pandemic Influenza Act of 2022; Pandemic and All-Hazards Preparedness Reauthorization; Department of Defense and Veterans Administration acquisition of influenza vaccine
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
FY2024 Appropriations and supplemental appropriations; H.R. 9476 Protecting America from Seasonal and Pandemic Influenza Act of 2022; Pandemic and All-Hazards Preparedness Reauthorization; Department of Defense and Veterans Administration acquisition of influenza vaccine
Client expense: $190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
FY2024 Appropriations, FY2024 President's Budget proposals, supplemental appropriations, H.R. 9476 Protecting America from Seasonal and Pandemic Influenza Act of 2022, Pandemic and All-Hazards Preparedness Reauthorization, Department of Defense and Veterans Administration acquisition of influenza vaccine
Client expense: $210,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE
FY2023 Appropriations, FY2023 President's Budget proposals, supplemental appropriations, seasonal and pandemic influenza preparedness, H.R. 9476 Protecting America from Seasonal and Pandemic Influenza Act of 2022
Client expense: $230,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE
H.R. 9476 Protecting America from Seasonal and Pandemic Influenza Act of 2022; issues related to pandemic preparedness and seasonal and pandemic influenza preparedness.
Client expense: $230,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), SENATE
2022 · fourth_quarter · Health Issues
Public health data authority; H.R. 9476 Protecting America from Seasonal and Pandemic Influenza.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
PREVENT Pandemics Act (S3799) United States Innovation and Competition Act (S1260) America COMPETES Act of 2022 (HR4521) Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S4348) General Issues related to drug shortages (HR2870) General Issues related to strategic national stockpile (HR3635, S1693, S1974) General Issues related to COVID-19 General Issues related to drug cost oversight General Issues related to domestic manufacturing of pharmaceutical products General issues related to the Public Health Services Act Protecting America from Seasonal and Pandemic Influenza Act (HR9476)
Client expense: $554,860 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Health Issues
Federal funding and policy issues related to seasonal and pandemic influenza prevention, treatment, and response; H.R.9476, Protecting America from Seasonal and Pandemic Influenza Act of 2022
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Bills -H.R. 2163/S. 464 - Safe Step Act -S.1773 - Prescription Drug Pricing Dashboard Act -H.R. 5376 - Build Back Better Act -H.R. 3684- Infrastructure Investment and Jobs Act -H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act -S.2076/H.R. 3932 PASTEUR Act -S. 3799- PREVENT Pandemics Act -H.R.4521 - COMPETES Act of 2022 -S.1260 - United States Innovation and Competition Act of 2021 -H.R.6963 - Accelerated Approval Integrity Act of 2022 -H.R.6996 - Accelerating Access for Patients Act of 2022 -H.R. 2565 / S.2952 the FDA Modernization Act -H.R. 6972 - Give Kids a Chance Act -H.R. 1730 - STAT Act -H.R. 7032 - Increasing Transparency in Generic Drug Applications Act -H.R. 5030/S. 2706 - DIVERSE Trials Act -H.R. 6584 - DEPICT Act -H.R. 9476- Influenza Act of 2022 Issues -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing -Issues related to healthcare legislation -Patient access to Part B medicines during the COVID-19 public health emergency -Issues related to health equity, diversity, and inclusion in clinical trials -Issues related to advanced development and procurement of medical countermeasures (MCMs) -Issues related to patient assistance and access -Issues relating to privacy and securing the data of and personal information of consumers -Issues relating to medical research data -Issues relating to screening and diagnostics -Issues related to public health preparedness and response -Issues related to awareness about diabetic eye diseases in minority populations
| Democratic |
| CA |
| Salud O. Carbajal | Democratic | CA |
Client expense: $1,630,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE